Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey

TÖRÜNER M., BAŞARANOĞLU M., ATUĞ Ö., Senturk O., Akyuz F., Cekic C., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.33, sa.5, ss.406-413, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 5
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/tjg.2022.21868
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.406-413
  • Anahtar Kelimeler: Anti-TNF, Crohn's disease, quality of life, work productivity, ACTIVITY IMPAIRMENT QUESTIONNAIRE, INFLAMMATORY-BOWEL-DISEASE, CERTOLIZUMAB PEGOL, MAINTENANCE, ADALIMUMAB, TRIAL, INFLIXIMAB, REMISSION, MODERATE, OUTCOMES
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Patients with Crohn's disease experience major deterioration in work productivity and quality of life. We aimed to provide the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients with Crohn's disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36.